Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
September 03 2020 - 07:00AM
Business Wire
Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical
company focused on the formulation, development, and
commercialization of innovative therapies for diseases and
conditions of the eye, today announced that it will present and
host investor meetings at the following conferences:
2020 Wells Fargo Virtual Healthcare Conference Date:
Thursday, September 10, 2020 Analyst-hosted fireside chat: 4:00 PM
ET
H.C. Wainwright 22nd Annual Global Investment Conference
Date: Monday, September 14, 2020 Presentation Time: 1:30 PM ET
A live webcast of the presentations can be accessed by visiting
the Investors section of the Company’s website at
investors.ocutx.com.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused
on the formulation, development, and commercialization of
innovative therapies for diseases and conditions of the eye using
its proprietary bioresorbable hydrogel-based formulation
technology. Ocular Therapeutix’s first commercial drug product,
DEXTENZA, is FDA-approved for the treatment of ocular inflammation
and pain following ophthalmic surgery. Ocular Therapeutix recently
completed a Phase 3 clinical trial evaluating DEXTENZA for the
treatment of ocular itching associated with allergic
conjunctivitis. The Company’s earlier stage development assets
currently in Phase 1 trials include OTX-TIC (travoprost
intracameral implant) for the reduction of intraocular pressure in
patients with primary open-angle glaucoma and ocular hypertension,
OTX-CSI (cyclosporine intracanalicular insert) for the treatment of
the signs and symptoms of dry eye disease and OTX-TKI (axitinib
intravitreal implant) for the treatment of retinal diseases. Also,
Ocular Therapeutix is currently developing OTX-DED (dexamethasone
intracanalicular insert) for the treatment of episodic dry eye and,
in collaboration with Regeneron, OTX-AFS (aflibercept
suprachoroidal injection) for an extended-delivery formulation of
aflibercept for the treatment of retinal diseases. Ocular
Therapeutix's first product, ReSure® Sealant, is FDA-approved to
seal corneal incisions following cataract surgery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200903005193/en/
Investors Ocular Therapeutix Donald Notman Chief
Financial Officer dnotman@ocutx.com
or
Westwicke, an ICR Company Chris Brinzey, 339-970-2843
chris.brinzey@westwicke.com
Media Ocular Therapeutix Scott Corning Senior Vice
President, Commercial scorning@ocutx.com
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Feb 2024 to Mar 2024
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Mar 2023 to Mar 2024